Tradestie Institutional Equity Comparison Engine

CING vs AZN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AZN Overall Edge

AZN Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AstraZeneca PLC (AZN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CING trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus AZN at 16.3x Forward P/E and 25.8% operating margin (+6.7% YoY). In options structure, CING sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro) against AZN sits in UNCLASSIFIED (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner AZN
CING N/M vs AZN 16.3x Fwd P/E
Growth & Margin Winner AZN
Op Margin 0.0% vs 25.8% ยท YoY +0.0% vs +6.7%
Momentum & Technical Winner AZN
1Y +36.4% vs +2.5% ยท 52W Pos 18% vs 49%
Options & Structure Winner AZN
BREAKDOWN (16th %ile IV) vs UNCLASSIFIED (8th %ile IV)
CING NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap $62.5M
1M Return +9.17%
1Y Return +36.39%
Forward P/E N/M
Unified AI Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0
AZN NASDAQ
AstraZeneca PLC
Pharmaceutical Preparations
$182.62
-0.76% 1D
Market Cap $286.1B
1M Return +11.38%
1Y Return +2.48%
Forward P/E 16.3x
Unified AI Score
44.8 / 100 HOLD
Tech 32.0 Fund 38.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CING +36.39% AZN +2.48% Spread: +33.91 pp (CING Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CING TTM Op. Margin: 0.0% AZN TTM Op. Margin: 25.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs AZN. Trailing 12-month operating profitability (CING 0.0% vs AZN 25.8%) and valuation multiples (CING N/M vs AZN 16.3x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CING (0) vs AZN (9)
Institutional Metric CING AZN Criterion Row Winner
Market Capitalization Scale $62.5M $286.1B Larger Scale AZN
Trailing P/E Ratio Valuation N/M 26.1x Lower Multiple AZN
Forward P/E Ratio Valuation N/M 16.3x Lower Multiple AZN
Revenue Growth (YoY) Growth +0.0% +6.7% Higher Growth AZN
Operating Margin (TTM) Profitability 0.0% 25.8% Higher Margin AZN
Net Profit Margin Profitability 0.0% 17.7% Higher Margin AZN
Return on Equity (ROE) Capital Efficiency -198.7% 22.6% Higher ROE AZN
52-Week Range Position Momentum 18% ($3โ€“$12) 49% ($153โ€“$213) Stronger Trend AZN
Beta / 30D Volatility Risk Regime 1.13ฮฒ ยท 117% Vol 0.04ฮฒ ยท 32% Vol Lower Realized Risk AZN
Unified Institutional Score Composite Signal 44.8 / 100 (HOLD) 44.8 / 100 (HOLD) Higher Composite Tie

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CING vs AZN Buy Guide
CING BREAKDOWN
170d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live CING Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AZN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live AZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CING nor AZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.